Patient portal

PINOCCHIO (multiple types of cancer)

Clinical study in children on the metabolism, distribution and excretion of chemotherapy and kinase inhibitors in the body (pharmacokinetics).

Recruiting

Who can enter

  • Children receiving chemotherapy or kinase inhibitors (KIs) as standard of care

  • Age ≤18 years


Goal

In the PINOCCHIO study we investigate to what extent a young child's body handles chemotherapy or kinase inhibitors (KIs) differently than an adult or an older child's body. We do so by measuring the concentration of the drug in the blood. This allows us to find out if the dose needs to be adjusted for children.  

In stratum I (the chemotherapy stratum of the study), we look at commonly used chemotherapy agents: carboplatin, cisplatin, cytarabine, dactinomycin, daunorubicin, doxorubicin, etoposide, methotrexate, and vincristine.

Stratum II (the kinase inhibitor stratum of the study) is about different classes of KIs (ALK, BCR-ABL, RAS-pathway, VEGF-R, BCL2, mTOR, FLT3 and NTRK inhibitors, and multi kinase inhibitors). 


Background

Most of the information on the pharmacokinetics of chemotherapeutic agents and KIs is based on research in adults. This information is also used for children, without knowing whether this is correct for this patient group.

A child's body is in full development during the first years of life. As a result, the metabolism, distribution, and excretion of the chemotherapeutic agent or KI in the body, also known as pharmacokinetics, may be different. The lack of information about how a child’s body processes these drugs may lead to overdosing or underdosing, resulting in higher risk for side effects or less effectiveness of the treatment. With this study we want to look at the differences in pharmacokinetics between adults and children of different ages, in order to find out whether the treatment dosage should be adapted for children.

Children participating in this study will have extra blood samples taken at several times after the administration of chemotherapy or KI. No changes will be made to the chemotherapy or KI treatment when a child participates in this study.

In order to participate in a study please refer to your/your child’s doctor.


Last reviewed

June 5, 2026

Study details

The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.